Cancer Therapy

The addition of setanaxib to pembrolizumab in adults with squamous cell carcinoma of the head and neck conferred significant improvement in both PFS and OS, according to a topline data release from the agent’s manufacturer.

Less than half of the cancer therapies granted FDA accelerated approval showed meaningful improvement in survival or quality-of-life, study results presented at American Association for Cancer Research Annual Meeting showed.

Fewer than one-third of recently approved molecular-targeted cancer therapies demonstrated “substantial patient benefits,” according to data published in JAMA Oncology.

Pfizer Inc. and its chairman/CEO, Albert Bourla, PhD, will be awarded the 2024 AACR Outstanding Achievement Award for Service to Cancer Science and Medicine during the American Association for Cancer Research Annual Meeting in San Diego.

The Lymphoma Research Foundation formed a multidisciplinary consortium dedicated to advancing and harmonizing treatment for adolescents and young adults with lymphoma.

To help individuals who undergo cancer treatment lead healthier lives, Stacyann Bailey, PhD, has one overarching professional mission — to prevent bones from breaking.

Sleep apnea could be an early indicator of cancer therapy-related cardiomyopathy, according to new data presented at the American College of Cardiology Advancing the Cardiovascular Care of the Oncology Patient course.

The addition of immunotherapy to perioperative conventional cancer therapy appeared linked to more grade 3 to grade 4 treatment related adverse events, according to findings published in The Lancet Oncology.

An electronic consult program for patients who developed endocrine immune-related adverse events has considerably reduced health care utilization.

Text-based e-triage can select individuals for a fast-track process that allows them to proceed directly to infusion, saving as much as 66 minutes total care time, according to a study presented at ASCO Quality Care Symposium.